FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2596793635> ?p ?o ?g. }

• W2596793635 endingPage "5036" @default.
• W2596793635 startingPage "5036" @default.
• W2596793635 abstract "Abstract Previous studies have shown that FAMP in combination with CTX seems to have a significant advantage over single-agent FAMP in patients with relapsed CLL who had previously received alkylators or alkylators plus fludarabine, but are still fludarabine-sensitive. Despite the improved response rates, patients who achieve CR eventually relapse and require alternate therapies. The high rate of relapse in CLL affirms the need for improved treatments, which reduce or eliminate residual disease (MRD) to induce “better quality,” more durable responses. The monoclonal antibody alemtuzumab (Campath®), which is directed towards the CD52 antigen expressed on the surface of B-CLL cells, acts synergistically with fludarabine in vitro and appears to have synergistic activity in vivo. Alemtuzumab is one of a few single agents that has demonstrated the ability to eliminate minimal residual disease in CLL. Therefore, we designed a phase II study to determine the efficacy and safety of a 4-week combination regimen consisting of FAMP, CTX, and alemtuzumab (FCC) in relapsed patients with CLL. Objectives of this study also included the evaluation of the overall response rate (ORR), duration of response (DR), and the presence of MRD following treatment with FCC. Patients received FCC after a short period of alemtuzumab dose escalation, from 1 mg to 3 mg to 10 mg on consecutive days. The FCC regimen consisted of FAMP 40 mg/m2/day PO (Days 1–3), CTX 250 mg/m2/day PO (Days 1–3), followed by alemtuzumab 10 mg SC (Days 1–3). This combination was repeated on Day 29 for up to 6 cycles. MRD was measured by 4-color flow cytometry and consensus primer PCR. Nine patients (7 male and 2 female), have been enrolled in this trial. The median age of patients was 60.3 years (range, 43–78 years); 2 patients (22%) were in Binet stage C, 3 patients were in stage A and 4 patients were in stage B. Median number of prior treatment regimens was 2 (range, 1–3). Currently, 3 patients completed treatment, and 2 patients received 3 courses while the remaining 4 patients completed the first course. Among the 3 patients who completed treatment, 1 achieved a complete response (CR) and 2 patients a partial response (PR). MRD negativity was achieved in the peripheral blood in 1 patient. No CMV reactivation has been observed. No opportunistic infections have been recorded. Hematologic toxicity was manageable: 2 patients required G-CSF support. No nonhematologic toxicity was documented. This preliminary data on safety and efficacy of this regimen are encouraging and warrant further study." @default.
• W2596793635 created "2017-03-23" @default.
• W2596793635 creator A5008040655 @default.
• W2596793635 creator A5008054206 @default.
• W2596793635 creator A5018652598 @default.
• W2596793635 creator A5039819830 @default.
• W2596793635 creator A5040532466 @default.
• W2596793635 creator A5066134624 @default.
• W2596793635 creator A5071534708 @default.
• W2596793635 creator A5088993245 @default.
• W2596793635 creator A5090348551 @default.
• W2596793635 date "2005-11-16" @default.
• W2596793635 modified "2023-09-29" @default.
• W2596793635 title "Combination of Fludarabine (FAMP) Cyclophosphamide (CTX) and Alemtuzumab for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)." @default.
• W2596793635 doi "https://doi.org/10.1182/blood.v106.11.5036.5036" @default.
• W2596793635 hasPublicationYear "2005" @default.
• W2596793635 type Work @default.
• W2596793635 sameAs 2596793635 @default.
• W2596793635 citedByCount "2" @default.
• W2596793635 crossrefType "journal-article" @default.
• W2596793635 hasAuthorship W2596793635A5008040655 @default.
• W2596793635 hasAuthorship W2596793635A5008054206 @default.
• W2596793635 hasAuthorship W2596793635A5018652598 @default.
• W2596793635 hasAuthorship W2596793635A5039819830 @default.
• W2596793635 hasAuthorship W2596793635A5040532466 @default.
• W2596793635 hasAuthorship W2596793635A5066134624 @default.
• W2596793635 hasAuthorship W2596793635A5071534708 @default.
• W2596793635 hasAuthorship W2596793635A5088993245 @default.
• W2596793635 hasAuthorship W2596793635A5090348551 @default.
• W2596793635 hasConcept C126322002 @default.
• W2596793635 hasConcept C143998085 @default.
• W2596793635 hasConcept C2776694085 @default.
• W2596793635 hasConcept C2776755627 @default.
• W2596793635 hasConcept C2777609679 @default.
• W2596793635 hasConcept C2777938653 @default.
• W2596793635 hasConcept C2778461978 @default.
• W2596793635 hasConcept C2779015954 @default.
• W2596793635 hasConcept C2779263901 @default.
• W2596793635 hasConcept C2779823535 @default.
• W2596793635 hasConcept C2781413609 @default.
• W2596793635 hasConcept C2911091166 @default.
• W2596793635 hasConcept C71924100 @default.
• W2596793635 hasConcept C90924648 @default.
• W2596793635 hasConceptScore W2596793635C126322002 @default.
• W2596793635 hasConceptScore W2596793635C143998085 @default.
• W2596793635 hasConceptScore W2596793635C2776694085 @default.
• W2596793635 hasConceptScore W2596793635C2776755627 @default.
• W2596793635 hasConceptScore W2596793635C2777609679 @default.
• W2596793635 hasConceptScore W2596793635C2777938653 @default.
• W2596793635 hasConceptScore W2596793635C2778461978 @default.
• W2596793635 hasConceptScore W2596793635C2779015954 @default.
• W2596793635 hasConceptScore W2596793635C2779263901 @default.
• W2596793635 hasConceptScore W2596793635C2779823535 @default.
• W2596793635 hasConceptScore W2596793635C2781413609 @default.
• W2596793635 hasConceptScore W2596793635C2911091166 @default.
• W2596793635 hasConceptScore W2596793635C71924100 @default.
• W2596793635 hasConceptScore W2596793635C90924648 @default.
• W2596793635 hasIssue "11" @default.
• W2596793635 hasLocation W25967936351 @default.
• W2596793635 hasOpenAccess W2596793635 @default.
• W2596793635 hasPrimaryLocation W25967936351 @default.
• W2596793635 hasRelatedWork W2082620902 @default.
• W2596793635 hasRelatedWork W2362661449 @default.
• W2596793635 hasRelatedWork W2594236670 @default.
• W2596793635 hasRelatedWork W2596793635 @default.
• W2596793635 hasRelatedWork W2755812911 @default.
• W2596793635 hasRelatedWork W2794302045 @default.
• W2596793635 hasRelatedWork W2958355556 @default.
• W2596793635 hasRelatedWork W2980870211 @default.
• W2596793635 hasRelatedWork W3014972780 @default.
• W2596793635 hasRelatedWork W3160469825 @default.
• W2596793635 hasVolume "106" @default.
• W2596793635 isParatext "false" @default.
• W2596793635 isRetracted "false" @default.
• W2596793635 magId "2596793635" @default.
• W2596793635 workType "article" @default.